Infliximab maintenance therapy for fistulizing Crohn's disease - Wikidata - wikimedia - TriplyDB

Infliximab maintenance therapy for fistulizing Crohn's disease

Infliximab maintenance therapy for fistulizing Crohn's disease

http://www.wikidata.org/entity/Q28246982

about

Epidemiology and clinical course of Crohn's disease: results from observational studies European evidence based consensus on the diagnosis and management of Crohn's disease: special situations Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease Thalidomide and thalidomide analogues for induction of remission in Crohn's disease Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Postoperative enterocutaneous fistula: when to reoperate and how to succeed The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease Inflammatory bowel disease surgery in the biologic era Advances in the development of new biologics in inflammatory bowel disease Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Ustekinumab for the treatment of Crohn's disease: can it find its niche?Economic implications of biological therapy for Crohn's disease Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Medical Therapy of Perianal Crohn's Disease Pharmacologic therapy for inflammatory bowel disease refractory to steroids Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Inflammatory pathways of importance for management of inflammatory bowel disease Infliximab-Related Infusion Reactions: Systematic Review Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Use of the tumor necrosis factor-blockers for Crohn's disease Ustekinumab in Crohn's disease: evidence to date and place in therapy Transperineal ultrasonography in perianal Crohn disease: A valuable imaging modality Review article: Infliximab therapy for inflammatory bowel disease--seven years on Perianal Crohn's disease.Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Management of complex perianal Crohn's disease A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency Medical management of Crohn's disease: current therapy and recent advances.Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Inflammatory Bowel Disease in Children and Adolescents

P2860

Q22241217-10EDD9CE-9155-4095-84C2-21BECC6D5851 Q22242050-AC0205FA-E370-43BA-B346-01269449D137 Q22242347-4FB46344-F038-4C9B-B360-89998AF8C2C3 Q24241489-49DFD6BA-B0C0-41B5-B50E-114AF268908C Q24241766-C6223CD2-4F2D-46FF-8045-A67B8C928D10 Q24242101-EF57809F-4BB5-44C2-8650-8D00AF390AE2 Q24245127-18B899F9-4F19-4297-A735-94E9E5E72F65 Q24653675-54DC4E8B-743A-44DF-93FF-2F1D7BEA223F Q26740549-E69141A4-1274-47CE-A0D6-0621098E3F5F Q26745627-7D57E153-F35C-4225-9387-67FD5FB18D0E Q26745782-CE4743B2-4270-4509-B3B6-98BBA2F2964E Q26750456-7AA2B467-DAAD-4DB1-A41C-1499877A2659 Q26771890-99A4E321-154C-4F22-A98A-E7AEA796E7F1 Q26772179-B4068C70-8677-496E-BCE2-D118905B7924 Q26775240-669C6D3C-9F6C-44DE-BD17-41F09127508F Q26777409-F3E811CC-BB08-43D0-BFF0-CB883C85DB3C Q26777429-288CD3AD-CAA1-4C6C-ADCA-0647175ECD65 Q26777722-98A03E53-7180-412E-9335-CD3E9718BBEB Q26796415-211B662B-D81A-4BF7-9435-37ACFA709ECE Q26827444-4B583080-7512-4330-BA43-56548F5EBD47 Q26829392-46155108-C2BD-4D84-B0A7-DEF59A0B7FCC Q26829488-1572F259-D5B1-4E3E-A611-E2E2C374BFAE Q26991673-DECEFDA0-684E-48CF-A265-A535F66D5BA1 Q26994776-E75C10C4-A08E-40BD-A6B7-1E13B87A67E3 Q26999078-8B1ECDB6-41C4-4F45-9032-C01023548DED Q27005445-8E014C6D-BC8C-43B2-B2DC-7A53DC980561 Q27013835-DB1BD589-690D-4196-A273-2DE62B70B4C7 Q27021612-1FFA3B73-702F-43FC-94ED-8EB1FC15B8EF Q27030762-BDF3B7BF-0487-4D7D-9A92-BB951489E181 Q28073787-D5469769-FE6D-48D7-B875-C71A5C680ECC Q28088575-353AD2B6-2006-4AE2-BE43-BBE9E5AF3CF3 Q28294134-F958B014-5A9B-4BB4-A60F-A51671EF6023 Q29346975-5B71AF19-58DC-4097-889E-5492ECEEFDA9 Q30234628-D350DE9B-CE2E-4940-8608-85AD4187A17E Q30239850-E9D801A9-A4B4-4440-BB3E-7A33443E08CA Q30430605-D8C1B990-FC7C-4BBA-B31B-1B2AB55D99CC Q30450875-D7B98C36-55B8-4CB4-AE1C-78A0E5789E6F Q30526431-E5AC410F-64F0-4A19-BBEB-65CF32825AE6 Q30675199-DA2385C8-973B-4F5F-B24B-F1808B43E5C7 Q30695348-699CF9A7-061D-40A1-91FA-665E56369FB1

P2860

Infliximab maintenance therapy for fistulizing Crohn's disease

http://www.wikidata.org/entity/Q28246982

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Infliximab maintenance therapy for fistulizing Crohn's disease

@ast

Infliximab maintenance therapy for fistulizing Crohn's disease

@en

Infliximab maintenance therapy for fistulizing Crohn's disease

@nl

type

label

Infliximab maintenance therapy for fistulizing Crohn's disease

@ast

Infliximab maintenance therapy for fistulizing Crohn's disease

@en

Infliximab maintenance therapy for fistulizing Crohn's disease

@nl

prefLabel

Infliximab maintenance therapy for fistulizing Crohn's disease

@ast

Infliximab maintenance therapy for fistulizing Crohn's disease

@en

Infliximab maintenance therapy for fistulizing Crohn's disease

@nl

P1433

Q28246982-03ECB29B-2DC8-48C2-83E7-8B59F34A8B39

P1476

Q28246982-A19EA18D-8E99-461A-9F21-2DB5B088AACF

P2093

Q28246982-034B2DB9-FB4B-434C-826A-F77F4554AD51

Q28246982-03BAC892-244C-41CD-83E8-04E3EC313AD2

Q28246982-2DF9E4EE-82EE-40FA-8BD4-3E6206E6C654

Q28246982-312B0102-2630-4680-98EA-F8D90D6DDA8E

Q28246982-4427F713-992B-4E2F-A81B-FED95D7E4F5C

Q28246982-5AA6FCAB-200E-436C-8CD7-979F1B15AB6D

Q28246982-68E97A5E-BCD2-4C89-BC63-D8D436103EEE

Q28246982-972296CB-785F-4085-99DE-603504FFC320

Q28246982-AA9F9934-3D88-4350-98B1-5C230008DAEA

Q28246982-AF067248-6809-473D-875B-2CCD593FA9B7

P304

Q28246982-0CE8832D-75AF-4383-B3D9-07048DD47C71

P31

Q28246982-387D1C36-4A9D-4819-B139-82515BB9BEF3

P3181

Q28246982-A6595501-C748-4DA5-9A20-EF32C5AA57E5

P356

Q28246982-10455DC3-164E-4866-92EB-C1F9B0047771

P407

Q28246982-F8CCC93C-5035-4507-8149-0D06B3E37471

P433

Q28246982-E9ED4346-D857-4D28-B10D-9598618FE731

P478

Q28246982-C0F712F6-15C2-4118-91A4-93E522DD02CC

P50

Q28246982-24CEFC35-66A2-41F2-B6F7-02D230585357

Q28246982-CA4A0F76-0303-4F4F-B183-423B97D9BD95

P577

Q28246982-ABB72F26-A117-4806-AFE9-4B6668463166

P698

Q28246982-2E80E03F-ED63-4AF3-85BA-58B69C660496

P921

Q28246982-3643DC26-9D79-4D61-BAF6-6CEBA309336E

P3181

P356

P1433

The New England Journal of Medicine

P1476

Infliximab maintenance therapy for fistulizing Crohn's disease

@en

P2093

Bret A Lashner

http://www.w3.org/2001/XMLSchema#string

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Charles N Bernstein

http://www.w3.org/2001/XMLSchema#string

Daniel Rachmilewitz

http://www.w3.org/2001/XMLSchema#string

Douglas C Wolf

http://www.w3.org/2001/XMLSchema#string

Frank H Anderson

http://www.w3.org/2001/XMLSchema#string

Gary Wild

http://www.w3.org/2001/XMLSchema#string

Jane E Onken

http://www.w3.org/2001/XMLSchema#string

Joshua R Korzenik

http://www.w3.org/2001/XMLSchema#string

Marion A Blank

http://www.w3.org/2001/XMLSchema#string

P304

876-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2727311

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA030815

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Brian G. Feagan

P577

2004-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14985485

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease